The content on this site is intended for healthcare professionals only
Welcome to APCCC 2021
Prof Silke Gillessen and Prof Aurelius Omlin
23 Sep 2021
ESMO 2021 Roundup
Dr Bishal Gyawali - Queen's University, Kingston, Canada
22 Sep 2021
PARP inhibitors in prostate cancer: Case based testing and clinical decisions
Dr Neal Shore and Prof Fred Saad
20 Sep 2021
OncoAlert and ecancer - ESMO 2021 Day 4
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
20 Sep 2021
Abiraterone acetate plus prednisolone added to ADT + docetaxel, gives 25% reduct...
Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France
19 Sep 2021
OncoAlert and ecancer - ESMO 2021 Day 3
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
19 Sep 2021
STAR: First-line sunitinib or pazopanib for locally advanced and/or metastatic r...
Prof Janet Brown - University of Sheffield, Sheffield, United Kingdom
19 Sep 2021
Nivolumab with alternatively scheduled ipilimumab in first-line treatment of adv...
Dr Naveen Vasudev - Leeds Cancer Centre, Leeds, UK
19 Sep 2021
High- vs low-dose pre-operative ipilimumab and nivolumab in locoregionally advan...
Dr Jeroen Van Dorp - Netherlands Cancer Institute, Amsterdam, The Netherlands
18 Sep 2021
Cabozantinib in combination with atezolizumab in patients with mCRPC
Prof Neeraj Agarwal - University of Utah School of Medicine, Salt Lake CIty, US...
18 Sep 2021
OncoAlert and ecancer - ESMO 2021 Day 2
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
18 Sep 2021
Erdafitinib (ERDA) or ERDA plus cetrelimab for patients with metastatic or local...
Prof Thomas Powles - Queen Mary University of London, London, UK
17 Sep 2021
